全文获取类型
收费全文 | 26887篇 |
免费 | 2814篇 |
国内免费 | 14篇 |
出版年
2023年 | 116篇 |
2022年 | 98篇 |
2021年 | 544篇 |
2020年 | 351篇 |
2019年 | 420篇 |
2018年 | 503篇 |
2017年 | 509篇 |
2016年 | 780篇 |
2015年 | 1308篇 |
2014年 | 1384篇 |
2013年 | 1496篇 |
2012年 | 2044篇 |
2011年 | 2019篇 |
2010年 | 1342篇 |
2009年 | 1166篇 |
2008年 | 1600篇 |
2007年 | 1708篇 |
2006年 | 1342篇 |
2005年 | 1382篇 |
2004年 | 1390篇 |
2003年 | 1293篇 |
2002年 | 1218篇 |
2001年 | 379篇 |
2000年 | 356篇 |
1999年 | 325篇 |
1998年 | 312篇 |
1997年 | 184篇 |
1996年 | 148篇 |
1995年 | 154篇 |
1994年 | 173篇 |
1993年 | 143篇 |
1992年 | 217篇 |
1991年 | 214篇 |
1990年 | 171篇 |
1989年 | 172篇 |
1988年 | 160篇 |
1987年 | 163篇 |
1986年 | 152篇 |
1985年 | 176篇 |
1984年 | 176篇 |
1983年 | 128篇 |
1982年 | 102篇 |
1981年 | 130篇 |
1980年 | 105篇 |
1979年 | 103篇 |
1978年 | 107篇 |
1977年 | 75篇 |
1976年 | 87篇 |
1974年 | 92篇 |
1971年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Ronac Mamtani James D. Lewis Frank I. Scott Tariq Ahmad David S. Goldberg Jashodeep Datta Yu-Xiao Yang Ben Boursi 《PLoS medicine》2016,13(4)
BackgroundSeveral prior studies have found an association between statin use and reduced risk of colorectal cancer. We hypothesized that these findings may be due to systematic bias and examined the independent association of colorectal cancer risk with statin use, serum cholesterol, and change in cholesterol concentration.ConclusionsAlthough the risk of colorectal cancer was lower in statin users versus nonusers, no difference was observed among those who continued versus discontinued statin therapy, suggesting the potential for indication bias. The association between decreased serum cholesterol and colorectal cancer risk suggests a cholesterol-lowering effect of undiagnosed malignancy. Clinical judgment should be used when considering causes of cholesterol reduction in patients, including those on statin therapy. 相似文献
3.
4.
Jennifer Dumont Don Euwart Baisong Mei Scott Estes Rashmi Kshirsagar 《Critical reviews in biotechnology》2016,36(6):1110-1122
Biotherapeutic proteins represent a mainstay of treatment for a multitude of conditions, for example, autoimmune disorders, hematologic disorders, hormonal dysregulation, cancers, infectious diseases and genetic disorders. The technologies behind their production have changed substantially since biotherapeutic proteins were first approved in the 1980s. Although most biotherapeutic proteins developed to date have been produced using the mammalian Chinese hamster ovary and murine myeloma (NS0, Sp2/0) cell lines, there has been a recent shift toward the use of human cell lines. One of the most important advantages of using human cell lines for protein production is the greater likelihood that the resulting recombinant protein will bear post-translational modifications (PTMs) that are consistent with those seen on endogenous human proteins. Although other mammalian cell lines can produce PTMs similar to human cells, they also produce non-human PTMs, such as galactose-α1,3-galactose and N-glycolylneuraminic acid, which are potentially immunogenic. In addition, human cell lines are grown easily in a serum-free suspension culture, reproduce rapidly and have efficient protein production. A possible disadvantage of using human cell lines is the potential for human-specific viral contamination, although this risk can be mitigated with multiple viral inactivation or clearance steps. In addition, while human cell lines are currently widely used for biopharmaceutical research, vaccine production and production of some licensed protein therapeutics, there is a relative paucity of clinical experience with human cell lines because they have only recently begun to be used for the manufacture of proteins (compared with other types of cell lines). With additional research investment, human cell lines may be further optimized for routine commercial production of a broader range of biotherapeutic proteins. 相似文献
5.
Autoimmune destruction of the pancreatic islets in Type 1 diabetes is mediated by both increased proinflammatory (Teff) and decreased regulatory (Treg) T lymphocytes resulting in a significant decrease in the Treg:Teff ratio. The non-obese diabetic (NOD) mouse is an excellent in vivo model for testing potential therapeutics for attenuating the decrease in the Treg:Teff ratio and inhibiting disease pathogenesis. Here we show for the first time that a bioreactor manufactured therapeutic consisting of a complex of miRNA species (denoted as TA1) can effectively reset the NOD immune system from a proinflammatory to a tolerogenic state thus preventing or delaying autoimmune diabetes. Treatment of NOD mice with TA1 resulted in a systemic broad-spectrum upregulation of tolerogenic T cell subsets with a parallel downregulation of Teff subsets yielding a dramatic increase in the Treg:Teff ratio. Moreover, the murine-derived TA1 was highly effective in the inhibition of allorecognition of HLA-disparate human PBMC. TA1 demonstrated dose-responsiveness and exhibited equivalent or better inhibition of allorecognition driven proliferation than etanercept (a soluble TNF receptor). These findings demonstrate that miRNA-based therapeutics can effectively attenuate or arrest autoimmune disease processes and may be of significant utility in a broad range of autoimmune diseases including Type 1 diabetes. 相似文献
6.
Patterns generated from ecological surveys are rarely tested in similar habitats to assess the accuracy of predictions. Testing empirically derived predictions provides a strong tool for establishing the consistency of general patterns in ecology. We test the consistency of beetle community associations with habitat complexity in open canopy forests and make both community and morphospecies-level comparisons with results from a previous study. We use Normalized Difference Vegetation Indices (NDVIs) from remote sensing as a surrogate for habitat complexity. The positive relationships between NDVIs and site-based beetle species richness and abundance were consistent in open canopy forests both south and north of Sydney, Australia. NDVIs were also useful for predicting differences in beetle composition in open canopy forests. Taxon-specific responses to NDVI differences in 'southern forests' were very similar to responses in 'northern forests', most likely reflecting beetle trophic roles. This study shows that NDVIs can be used as rapid biodiversity indicators, when integrated with identified faunal responses to vegetation structure, provided that the lower vegetation strata may be measured by remote sensing. 相似文献
7.
Julie A. Eclov Qingwen Qian Rebecca Redetzke Quanhai Chen Steven C. Wu Chastity L. Healy Steven B. Ortmeier Erin Harmon Gregory C. Shearer Timothy D. O’Connell 《Journal of lipid research》2015,56(12):2297-2308
Heart failure with preserved ejection fraction (HFpEF) is half of all HF, but standard HF therapies are ineffective. Diastolic dysfunction, often secondary to interstitial fibrosis, is common in HFpEF. Previously, we found that supra-physiologic levels of ω3-PUFAs produced by 12 weeks of ω3-dietary supplementation prevented fibrosis and contractile dysfunction following pressure overload [transverse aortic constriction (TAC)], a model that resembles aspects of remodeling in HFpEF. This raised several questions regarding ω3-concentration-dependent cardioprotection, the specific role of EPA and DHA, and the relationship between prevention of fibrosis and contractile dysfunction. To achieve more clinically relevant ω3-levels and test individual ω3-PUFAs, we shortened the ω3-diet regimen and used EPA- and DHA-specific diets to examine remodeling following TAC. The shorter diet regimen produced ω3-PUFA levels closer to Western clinics. Further, EPA, but not DHA, prevented fibrosis following TAC. However, neither ω3-PUFA prevented contractile dysfunction, perhaps due to reduced uptake of ω3-PUFA. Interestingly, EPA did not accumulate in cardiac fibroblasts. However, FFA receptor 4, a G protein-coupled receptor for ω3-PUFAs, was sufficient and required to block transforming growth factor β1-fibrotic signaling in cultured cardiac fibroblasts, suggesting a novel mechanism for EPA. In summary, EPA-mediated prevention of fibrosis could represent a novel therapy for HFpEF. 相似文献
8.
9.
Robert M Bennett Ronald Friend Kim D Jones Rachel Ward Bobby K Han Rebecca L Ross 《Arthritis research & therapy》2009,11(4):R120-14
Introduction
The Fibromyalgia Impact Questionnaire (FIQ) is a commonly used instrument in the evaluation of fibromyalgia (FM) patients. Over the last 18 years, since the publication of the original FIQ, several deficiencies have become apparent and the cumbersome scoring algorithm has been a barrier to widespread clinical use. The aim of this paper is to describe and validate a revised version of the FIQ: the FIQR. 相似文献10.